Abstract
Postmenopausal Hormone Replacement Therapy has been implicated in the development of four frequent female tumors: endometrial cancer, breast cancer, ovarian cancer and colorectal cancer. Estrogens are only weak genotoxic, mutagenic carcinogens, but could induce tumors by way of accumulation of incessant DNA replication damage. While estrogen (only) hormone replacement therapy (ERT) increases the risk of endometrial carcinoma and probably of ovarian carcinoma, ERT seems to be neutral for the breast and colorectal cancer. With combined estrogen progestagen replacement therapy (HRT), there is no increased risk of endometrial cancer nor of ovarian cancer. The risk of breast cancer, however, is slightly increased with long-term use. Colorectal cancer risk is probably reduced with combined HRT use. Data are only available for oral use; for transdermal, intranasal and other use no data are available.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
